-+ 0.00%
-+ 0.00%
-+ 0.00%

Cabaletta Bio (CABA) Stock Looks Undervalued Even After Fresh Trial Data

Simply Wall St·11/16/2026 16:10:25
Listen to the news

Cabaletta Bio has seen its share price fall sharply over recent years, yet fresh clinical data has put the business back on the radar and raised a very specific question for investors about how today’s stock price lines up against its book value. With the market weighing promising trial results against a long record of share price declines, the issue is whether the current valuation still reflects the assets on its balance sheet or something quite different.

  • Over the past 3 years, Cabaletta Bio shares have declined about 92.9%, which puts the focus squarely on whether the remaining equity price is still anchored to the company’s underlying net assets.
  • New Phase 1/2 data for rese-cel in autoimmune diseases, along with plans for a potential Biologics License Application in myositis, can shape expectations for how efficiently the business might convert its current research pipeline into future assets that feed into book value over time.
  • Your read on Cabaletta Bio is one view; the desks covering it have another. See what analysts think Cabaletta Bio's shares could be worth.

For investors, the debate is whether Cabaletta Bio’s current share price is adequately explained by its book value when set against the broader industry average.

If you are weighing Cabaletta Bio against other beaten down ideas where valuation is also in focus, a focused stock screen can help you frame the next step in your research. You can start with 35 high quality undervalued stocks.

Does Cabaletta Bio Look Undervalued on Book Value?

P/B tends to matter most for a research stage biotech like Cabaletta Bio where hard assets and cash on the balance sheet loom larger than current earnings. On this yardstick, Cabaletta Bio trades on a P/B of about 1.0x, which means the market value is close to the book value of its net assets. The broader biotechs group sits nearer 1.8x, so the shares change hands at a sizeable discount to the sector’s average multiple.

Because the recent rese-cel data has lifted interest in the pipeline, yet the P/B ratio of 1.0x still trails that industry benchmark, the market seems to be pricing Cabaletta Bio as more asset backed and less dependent on franchise value than many peers. For readers, that gap highlights a stock that screens as undervalued on book value compared with the wider Biotechs industry, while still requiring careful work on trial risk, funding needs and potential future dilution before taking the ratio at face value. Explore the numbers behind Cabaletta Bio's P/B valuation.

NasdaqGS:CABA P/B Ratio as at Nov 2026
NasdaqGS:CABA P/B Ratio as at Nov 2026

The Cabaletta Bio Narrative: What Would Justify Today's Price?

Narratives pick up where the P/B puzzle for Cabaletta Bio leaves off by explaining which growth, margin and earnings paths would need to occur for the share price to move meaningfully above or below today's level. Each scenario on Simply Wall St's Community page links a fair value estimate to a specific mix of potential catalysts and risks, so you can track over time which version of Cabaletta Bio's story is actually unfolding in the data.

One of the top narratives on Cabaletta Bio: 89% undervalued

This narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

"The current valuation implies the market is cautious about Cabaletta Bio’s ability to translate encouraging remission rates, benign safety signals, payer interest and potential priority review voucher proceeds into long-term commercial value for the share price…"

Discover why this Narrative puts Cabaletta Bio at 89% undervalued.

One more Cabaletta Bio check that belongs beside the balance sheet

Before leaving Cabaletta Bio on a watchlist, it is worth asking who is steering the pipeline, how their incentives line up with long term outcomes, and whether that pay structure fits the risks on the table. See who runs Cabaletta Bio and how they are paid.